Sabine Duntze’s Post

Discover best practices to investigate novel blood cancer therapies with hematology experts Christopher Morley and Sari Heitner Enschede, MD. This insightful white paper explores how biotech companies can address the challenges around investigational agents for hematologic cancers, while considering patient diversity. https://bit.ly/4aThp5S #oncology #hematology #biotech #ClinicalTrials #diversity

🎯 DLL3 ADC: A Breakthrough in Oncology! 🎯 Innovative Antibody-Drug Conjugates (ADCs) targeting DLL3 are paving the way for transformative cancer therapies. 🧬 These advancements offer new hope in the fight against aggressive tumors. 🚀💉 IDEAYA Biosciences Hengrui Pharma Co.,Ltd Know complete story - https://lnkd.in/d4uCP2eD #CancerInnovation #OncologyBreakthrough #DLL3ADC #PharmaAdvancements #PatientCare

Fellow oncology professionals heading to ASCO next week - I created a planner containing information on all 83 oral abstract sessions for breast & lung cancer, including presenter details and the associated clinical trials. Happy to share this resource - please comment "planner" below if you'd like a copy, and wishing everyone smooth travels to Chicago! #Oncology #Biotech #Pharma

Discover the transformative potential of antibody-drug conjugates (ADCs) in targeted cancer therapy. Our latest presentation dives deep into the journey of ADC development, from Paul Ehrlich's early concept of "magic bullets" to their current status as a leading treatment modality. Learn about the intricate bioanalytical challenges, cutting-edge techniques, and regulatory milestones shaping the future of ADCs in oncology. #CancerResearch #ADCs #Bioanalysis #PrecisionMedicine #WuXiAppTec https://hubs.li/Q02zVC290

Did you know that only about 36% of patients diagnosed with lung cancer receive the right treatment? Access the AMCP Market Insights report, Bridging the Gaps in Precision Oncology: Opportunities in Non-Small Cell Lung Cancer, to discover how effective referral, utilization management, and advanced diagnostics can improve patient outcomes and reduce costs. Visit the AMCP Market Insights resource page to learn more: https://bit.ly/4efCk4W #managedcare #pharmacy #oncology

Bispecific antibody therapy is emerging as a promising option for patients with advanced cancer. Lee Pendleton, PharmD, from Arizona Oncology in Prescott, helps patients and their families better understand how this innovative therapy works, its potential benefits, and what to expect. 📖arizonaoncology.com/blog #BispecificAntibodies #CancerTherapy #Oncology #AdvancedCancer #Pharmacology #PatientCare #Prescott #Arizona

🔬 Sun Pharma Advanced Research Company Ltd. (SPARC) has teamed up with UCSF and Tiller Therapeutics to advance a promising pre-clinical oncology asset, aimed at addressing solid tumors with no current cure. 🌍 This collaboration could significantly impact the future of cancer treatment. Learn more about the terms of this groundbreaking partnership and what’s next for cancer research. 👉 Click the link to read more: https://lnkd.in/gYChjrek #CancerResearch #Oncology #PharmaPartnership #SPARC #UniversityofCalifornia

The illustrations in this presentation visually depict the key stages of ONX-1006's mechanism, including its journey through the bloodstream, binding to the tumor cell membrane, being engulfed through endocytosis, and releasing its PTX (chemotherapy drug) payload. These processes are designed to highlight ONX-1006's non-toxic effectiveness in delivering its therapeutic agent, leading to the eventual apoptosis and destruction of tumor cells. #Pancreaticcancer #CancerTreatment #CancerResearch #Oncology

Rocking the pink in honor of the Biotech CEO Sisterhood at #JPM25, Abdera Therapeutics CEO Lori Lyons-Williams details the company’s progress in advancing its radiopharmaceuticals-focused pipeline, including the recently initiated first-in-human Phase 1 clinical trial evaluating ABD-147 for the treatment of small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC)…and disclosing preclinical data on ABD-320, which is currently in IND-enabling studies.

2025 Transatlantic Exchange by Dana-Farber Cancer Institute and Gustave Roussy to Focus on Radioligand Therapy The “Radiopharmaceutical Therapy Meets Oncology” conference will take place on March 19, 2025, in Paris and be livestreamed globally. Supported by L'Institut Servier, the event will feature discussions on precision oncology, molecular imaging, and Radioligand Therapies. https://lnkd.in/dGAVVK-t #Cancer #CancerResearch #CancerTreatment #Medicine #Health #Conference #Collaboration #Oncology #OncoDaily